Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Tau-441 (2N4R) P301S Mutant Monomers

Human Recombinant Tau-441 (2N4R) P301S Mutant Monomers (CHO-expressed, N-glycosylated)

Product Specifications

Background

Mammalian N-glycosylation is present on CHO-secreted tau 2N4R, which contributes to slower migration on SDS-PAGE than E.coli or Baculovirus/Sf9 expressed tau (1, 2) . N-glycosylated tau has been identified in human AD-diseased brains, but not healthy brains, and may precede tau hyperphosphorylation (3, 4) . N-glycosylation of Tau has been demonstrated to affect its aggregation propensity (5) . The tau P301S mutation is associated with early onset neurodegeneration, and functionally reduces microtubule assembly and stimulates fibril assembly (6, 7) . Our CHO-expressed Tau 2N4R P301S will readily form fibrils in the absence of heparin and contains mammalian post-translational modifications that may better mimic tau in human AD-brains.

Product Name Alternative

MAPT, intracellular neurofibrillary tangles, NFTs, paired helical filaments, PHFs, 2N4R

UNSPSC

12352202

UN Code

Non-hazardous

Hazard Statement

Non-hazardous

Swiss Prot

P10636-8

Expression System

Chinese Hamster Ovary (CHO)

Host

Chinese Hamster Ovary (CHO)

Origin Species

Human

Target

Tau-441 (2N4R) P301S mutant (CHO-expressed, N-glycosylated)

Conjugation

N-term histidine tag & TEV site

Nature

Recombinant

Sequence

GGSHHHHHHHHHHGSGGSENLYFQGMAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVSGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL

Applications

WB | In vivo Assay | In vitro Assay

Field of Research

Neuroscience | Neurodegeneration | Alzheimer's Disease | Tangles & Tau

Purification Method

Affinity Purified and Size Exclusion

Purification

Affinity Purified and Size Exclusion

Limit Of Detection

Protein certified >95% pure on SDS-PAGE & Nanodrop analysis

Concentration

2 mg/ml or 5 mg/ml

Purity

>95%

Weight

0.05

Length

441 aa (excluding tag), 466 aa (including tag)

Buffer

1X PB pH 7.4

Molecular Weight

48.609 kDa

Precautions

Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.

Additionnal Information

CHO expression in mammalian cell line may lead to more “human” like phosphorylation/glycosylation patterns. For corresponding PFFs, see catalog# SPR-516.

References & Citations

1. Guo et al., 2019. A pathogenic tau fragment compromises microtubules, disrupts insulin signaling and induces the unfolded protein response. Acta Neuropathologica Communications. DOI: 10.1186/s40478-018-0651-9 2. Losev et al., 2020. Differential effects of putative N-glycosylation sites in human Tau on Alzheimer’s disease-related neurodegeneration. Cellular and Molecular Life Sciences. DOI: 10.1007/s00018-020-03643-3 3. Zhang et al., 2020. Integrative glycoproteomics reveals protein N-glycosylation aberrations and glycoproteomic network alterations in Alzheimer’s disease. Sci. Adv. DOI: 10.1126/sciadv.abc5802 4. Liu et al., 2002. Role of glycosylation in hyperphosphorylation of tau in Alzheimer’s disease. FEBS. DOI: 10.1016/S0014-5793(02)02228-7 5. Losev et al., 2019. Novel model of secreted human tau protein reveals the impact of the abnormal N-glycosylation of tau on its aggregation propensity. Sci. Rep. https://doi.org/10.1038/s41598-019-39218-x 6. Bugiani et al., 1999. Frontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau. J Neuropathol Exp Neurol. doi: 10.1097/00005072-199906000-00011. 7. Goedert and Crowther, 1999. Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett. DOI: 10.1016/s0014-5793(99)00508-6

Shipping Conditions

Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order.

Storage Conditions

-80ºC

Notes

CHO expression in mammalian cell line may lead to more “human” like phosphorylation/glycosylation patterns. For corresponding PFFs, see catalog# SPR-516.

Protein Length

441 aa (excluding tag), 466 aa (including tag)

Background Reference 01

1. Guo et al., 2019. A pathogenic tau fragment compromises microtubules, disrupts insulin signaling and induces the unfolded protein response. Acta Neuropathologica Communications. DOI: 10.1186/s40478-018-0651-9 2. Losev et al., 2020. Differential effects of putative N-glycosylation sites in human Tau on Alzheimer’s disease-related neurodegeneration. Cellular and Molecular Life Sciences. DOI: 10.1007/s00018-020-03643-3 3. Zhang et al., 2020. Integrative glycoproteomics reveals protein N-glycosylation aberrations and glycoproteomic network alterations in Alzheimer’s disease. Sci. Adv. DOI: 10.1126/sciadv.abc5802 4. Liu et al., 2002. Role of glycosylation in hyperphosphorylation of tau in Alzheimer’s disease. FEBS. DOI: 10.1016/S0014-5793 (02) 02228-7 5. Losev et al., 2019. Novel model of secreted human tau protein reveals the impact of the abnormal N-glycosylation of tau on its aggregation propensity. Sci. Rep. https://doi.org/10.1038/s41598-019-39218-x 6. Bugiani et al., 1999. Frontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau. J Neuropathol Exp Neurol. doi: 10.1097/00005072-199906000-00011. 7. Goedert and Crowther, 1999. Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett. DOI: 10.1016/s0014-5793 (99) 00508-6

AA Sequence

GGSHHHHHHHHHHGSGGSENLYFQGMAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVSGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL

Immunogen Species

Human

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Anti-Glutathione Reductase Polyclonal Antibody 2
MF-0075941-01 50 µL

Anti-Glutathione Reductase Polyclonal Antibody 2

Ask
View Details
Anti-Glutathione Reductase Polyclonal Antibody 2
MF-0075941-02 100 µL

Anti-Glutathione Reductase Polyclonal Antibody 2

Ask
View Details
Anti-Glutathione Reductase Polyclonal Antibody 2
MF-0075941-03 200 µL

Anti-Glutathione Reductase Polyclonal Antibody 2

Ask
View Details
CDC123 Polyclonal Antibody, AbBy Fluor™ 594 Conjugated
bs-7781R-BF594 100 µL

CDC123 Polyclonal Antibody, AbBy Fluor™ 594 Conjugated

Ask
View Details
C1QTNF3 siRNA (Mouse)
CRN0126-01 15 nmol

C1QTNF3 siRNA (Mouse)

Ask
View Details
C1QTNF3 siRNA (Mouse)
CRN0126-02 30 nmol

C1QTNF3 siRNA (Mouse)

Ask
View Details